Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,060Revenue (TTM) $M542Net Margin (%)8.3Altman Z-Score1.5
Enterprise Value $M1,884EPS (TTM) $1.2Operating Margin %24.1Piotroski F-Score3
P/E(ttm)24.0Beneish M-Score-1.7Pre-tax Margin (%)11.5Higher ROA y-yN
Price/Book1.910-y EBITDA Growth Rate %--Quick Ratio1.6Cash flow > EarningsY
Price/Sales2.05-y EBITDA Growth Rate %106Current Ratio2.0Lower Leverage y-yN
Price/Free Cash Flow9.6y-y EBITDA Growth Rate %-31.2ROA % (ttm)3.5Higher Current Ratio y-yN
Dividend Yield %--PEG0.2ROE % (ttm)8.6Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M36.9ROIC % (ttm)25.3Gross Margin Increase y-yN

Gurus Latest Trades with LCI

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
LCIRonald Muhlenkamp 2016-06-30 Reduce-0.02%$17.52 - $25.9
($21.35)
$ 28.7435%Reduce -0.54%404,405
LCIDavid Dreman 2016-06-30 Sold Out $17.52 - $25.9
($21.35)
$ 28.7435%Sold Out0
LCIRonald Muhlenkamp 2016-03-31 Buy 2.98%$17.23 - $40.12
($26.78)
$ 28.747%New holding406,600
LCIJoel Greenblatt 2016-03-31 Sold Out -0.49%$17.23 - $40.12
($26.78)
$ 28.747%Sold Out0
LCIDavid Dreman 2016-03-31 Buy $17.23 - $40.12
($26.78)
$ 28.747%New holding70
LCIJoel Greenblatt 2015-12-31 Reduce-0.11%$34.38 - $48.3
($40.96)
$ 28.74-30%Reduce -19.76%1,121,673
LCIDavid Dreman 2015-12-31 Sold Out $34.38 - $48.3
($40.96)
$ 28.74-30%Sold Out0
LCIJoel Greenblatt 2015-09-30 Reduce-0.16%$41.52 - $62.74
($54.88)
$ 28.74-48%Reduce -19.11%1,397,853
LCIDavid Dreman 2015-09-30 Buy $41.52 - $62.74
($54.88)
$ 28.74-48%New holding367
LCIJoel Greenblatt 2015-06-30 Add0.09%$52.6 - $71.15
($60.12)
$ 28.74-52%Add 11.07%1,728,019
LCIJoel Greenblatt 2015-03-31 Add0.27%$41.29 - $69.82
($56.77)
$ 28.74-49%Add 51.63%1,555,795
LCIJoel Greenblatt 2014-12-31 Add0.25%$40.3 - $57.52
($46.48)
$ 28.74-38%Add 238.24%1,026,029
LCIJoel Greenblatt 2014-09-30 Add0.12%$34.05 - $51.19
($39.77)
$ 28.74-28%Add 749.49%303,345
LCIJoel Greenblatt 2014-06-30 Buy 0.02%$29.62 - $49.76
($39.16)
$ 28.74-27%New holding35,709
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

LCI is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


LCI: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Landis G. MichaelPrincipal Accounting Officer 2016-09-15Sell4,334$32.3-11.02view
Maher James M.Director 2016-09-01Sell1,478$33.91-15.25view
Landis G. MichaelPrincipal Accounting Officer 2016-08-31Sell6,786$33.41-13.98view
Ehlinger RobertVP and CIO 2016-06-23Sell37,141$25.0614.68view
Ehlinger RobertVP and CIO 2016-06-20Sell62,859$25.413.15view
Ehlinger RobertVP of Logistics and CIO 2016-03-01Sell69,247$25.4113.11view
PAONESSA ALBERT IIIDirector 2016-02-05Buy2,500$24.5716.97view
GALVAN MARTIN PVP of Finance & CFO 2016-02-05Buy3,000$24.6516.59view
Taveira PaulDirector 2016-02-05Buy1,000$23.621.78view
Maher James M.Director 2016-02-05Buy1,000$23.8720.4view

Quarterly/Annual Reports about LCI:

News about LCI:

Articles On GuruFocus.com
Snow Capital Management's Top 5 New Buys May 12 2016 
A Short-Term Problem Creates Long-Term Opportunity in Lannett Company Jan 12 2016 
Healthcare Company Lannett Offers Compelling Value Oct 13 2015 
Royce 100 Fund Shareholder Letter Sep 20 2015 
Pharmaceutical Stock Picks For March Mar 04 2015 
Lannett Company Looks Cheap At First Glance; But It Is Actually Much Cheaper Than It Looks Dec 29 2014 
Lannett Company Inc Reports Operating Results (10-Q) Nov 12 2010 
Lannett Company Inc Reports Operating Results (10-K) Sep 24 2010 
Lannett Company Inc Reports Operating Results (10-Q) May 13 2010 
Lannett Company Inc Reports Operating Results (10-Q) Feb 11 2010 

More From Other Websites
ETF’s with exposure to Lannett Co., Inc. : September 27, 2016 Sep 27 2016
Lannett Co., Inc. breached its 50 day moving average in a Bearish Manner : LCI-US : September 23,... Sep 23 2016
LANNETT CO INC Files SEC form 8-K, Change in Directors or Principal Officers Sep 22 2016
Lannett Announces Resignation Of Mahendra Dedhiya, Ph.D., Chief Of Scientific Affairs Sep 22 2016
Lannett Announces Approval For Buprenorphine And Naloxone Sublingual Tablets, 2 mg/0.5 mg And 8 mg/2... Sep 20 2016
Lannett Announces Approval For Buprenorphine And Naloxone Sublingual Tablets, 2 mg/0.5 mg And 8 mg/2... Sep 20 2016
Lannett Announces Successful FDA Inspections of Three Facilities Sep 19 2016
Lannett Announces Successful FDA Inspections of Three Facilities Sep 19 2016
Lannett Co., Inc. breached its 50 day moving average in a Bullish Manner : LCI-US : September 13,... Sep 13 2016
It's Time To 'Moneyball' Your Portfolio Sep 12 2016
ETF’s with exposure to Lannett Co., Inc. : September 6, 2016 Sep 06 2016
LANNETT CO INC Financials Sep 02 2016
LANNETT CO INC Files SEC form 10-K, Annual Report Aug 29 2016
Lannett (LCI): Moving Average Crossover Alert Aug 29 2016
Zacks.com featured highlights: Xerox, Lannett Company, Semiconductor Manufacturing International,... Aug 29 2016
Lannett Co., Inc.: Gathering momentum, can it sustain its performance? Aug 25 2016
Lannett Co., Inc. :LCI-US: Earnings Analysis: 2016 By the Numbers : August 25, 2016 Aug 25 2016
LANNETT CO INC Files SEC form 8-K, Results of Operations and Financial Condition Aug 24 2016
Biotech Stocks Seesaw As M&A Hopes Meet New Pricing Fears Aug 24 2016
A Look At 5 Stocks Which Are Trending On Wednesday Aug 24 2016
ETF’s with exposure to Lannett Co., Inc. : August 24, 2016 Aug 24 2016
Lannett (LCI) Stock Jumps as Q4 Earnings, Revenue Beat Estimates Aug 24 2016
Lannett tops Street 4Q forecasts Aug 23 2016
Lannett Announces Record Net Sales For Fiscal 2016 Fourth-Quarter And Full-Year Aug 23 2016
Lannett To Report Fiscal 2016 Fourth-Quarter And Full-Year Financial Results, Host Conference Call... Aug 17 2016
Lannett Announces Senior Management Promotions Jul 25 2016
Lannett Announces Approval And Launch Of Paroxetine Extended Release Tablets USP, 12.5 Mg, 25 Mg,... Jul 11 2016
Lannett Receives FDA Approval For Diazepam Oral Solution, 5 mg/5 mL Jun 28 2016
Lannett Completes Repurchase Of Remaining $200 Million Of 12% Senior Notes Jun 20 2016
Lannett To Amend Credit Agreement To Repurchase Remaining $200 Million Of 12% Senior Notes Jun 14 2016
Lannett Receives FDA Approval For Neomycin Sulfate Tablets USP, 500 mg Jun 13 2016
Lannett Completes $50 Million-Pay Down Of 12% Senior Notes May 27 2016
Lannett To Voluntarily Pay Down $50 Million Of 12% Senior Notes May 26 2016
Lannett To Present At Bank Of America Merrill Lynch 2016 Health Care Conference On May 11 May 05 2016
Lannett Reports Solid Fiscal 2016 Third Quarter Results May 03 2016
Lannett To Report Fiscal 2016 Third-Quarter Financial Results And Host Conference Call On Tuesday,... Apr 28 2016
Lannett To Co-Develop Generic Insulin Product For $21 Billion U.S. Market Apr 22 2016
Lannett Announces Departure of President Michael Bogda Apr 11 2016
Lannett Receives FDA Approvals For Two Products Mar 29 2016
Lannett Revises Fiscal 2016 Full Year Guidance Mar 23 2016
Lannett meets 2Q profit forecasts Feb 03 2016
Lannett Announces Cost Savings And Restructuring Actions Feb 01 2016
Lannett to buy UCB unit to boost speciality generic drugs portfolio Sep 02 2015
Lannett beats Street 4Q forecasts Aug 25 2015
Lannett beats 3Q profit forecasts May 06 2015
Lannett beats 2Q profit forecasts Feb 04 2015
Lannett beats 1Q profit forecasts Nov 03 2014

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)